Strategy Papers

EU Medicines Agencies Network Strategy

The European Medicines Agency (EMA) Management Board and the Heads of Medicines Agencies (HMA) have adopted a common strategy to 2020 for the European medicines regulatory network.

This is the first time that a single strategy for the whole network has been developed. It outlines common challenges and opportunities and sets out joint key priorities and a high-level roadmap to achieve these over the next five years. The strategy also supports the strategic priorities of the European Commission and the European Union (EU) agenda on human and animal health.

EU Medicines Agencies Network Strategy to 2020 | pdf

 

Multi Annual Work Plan

After finalisation of the joint HMA/EMA strategy to 2020, the HMA developed a Multi Annual Work Plan (MAWP) to bring the joint overarching strategy into operation on the HMA level with the involvement of all National Competent Authorities. The MAWP has been developed by a HMA taskforce and was debated extensively in break-out sessions during the 2015 HMA plenary meetings in Luxemburg and Dubrovnik. The MAWP has been adopted on 17 February 2016 during the 83rd HMA meeting in Amsterdam.

Eleven topics were agreed as priority areas, namely:

  • Antimicrobial resistance
  • Availability of good quality appropriately authorised medicines
  • Competence development programme through the EU Network Training Centre
  • Developing an efficient, effective and collaborative approach on inspections to address sustainability
  • Innovation and access to new medicines
  • International collaboration
  • Optimisation of the regulatory operations
  • Responding to public and animal health emergencies
  • Strengthen surveillance
  • Implementation of the Telematics strategy
  • Support for better use of medicine

Multi Annual Work Plan (MAWP) | pdf